FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL OMB Number: 3235-0104

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Month/Day	//Year)	Statement	3. Issuer Name and Ticker or Trading Symbol XCYTE THERAPIES INC [XCYT]					
			Relationship of Reporting Person(s) to Issuer (Check all applicable) Director	10% Owner	5. If A	5. If Amendment, Date of Original Filed (Month/Day/Year)		
			X Officer (give title below)		ciow)	Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person		
			Chief Business Officer	and VP	,	-	e Reporting Person ire than One Reporting Person	
Table I - Non-Derivative Securities Beneficially Owned								
				3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		ure of Indirect Beneficial Ownership (Instr. 5)		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
Title of Derivative Security (Instr. 4)		ate	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
		Expiration Date	Title	Amount or Number of Shares	Security			
	01/21/2008(1)	01/21/2014	Common Stock	37,944	5.5	D		
	01/21/2008 ⁽²⁾	01/30/2012	Common Stock	34,782	5.5	D		
	(Month/Day	Table Table United State Sta	Table I - Non-De Table II - Non-De (e.g., puts, calls, v 2. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Date (Month/Day/Year) Date O1/21/2008(1) 01/21/2014	(Month/Day/Year) 03/10/2004 A. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X. Officer (give title below) Chief Business Officer X. Officer (give title below) Chief Business Officer Table II - Non-Derivative Securities Beneficially Owned (instr. 4) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Date (Instr. 4) Date Expiration Title 01/21/2008(1) 01/21/2014 Common Stock	(Month/Day/Year) 03/10/2004 A. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Director X. Officer (give title below) Chief Business Officer and VP Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities Beneficially Owned (nstr. 4) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 2. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Date Expiration Date Ittle Common Stock 3. Ownership For (D) or Indirect (I) (I) Amount of Securities Underlying Derivative Security (Instr. 4) Amount or Number of Shares 01/21/2008(1) 01/21/2014 Common Stock 3.7,944	A. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Other (specify below) Other (specify below) Chief Business Officer and VP Table I - Non-Derivative Securities Beneficially Owned (nstr. 4) Other (specify below) Other (specify belo	Common Stock Comm	

Explanation of Responses:

1. Shares shall vest at a rate of: 25% on January 21, 2004 and monthly thereafter until all shares are fully vested on January 21, 2008.

2. Shares shall vest at a rate of: 25% on January 21, 2004 and monthly thereafter until all shares are fully vested on January 21, 2008.

/s/ Joanna Lin Black, Attorney-in-Fact for Robert L. Kirkman

** Signature of Reporting Person

03/10/2004

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

** If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Kathi Cordova and Joanna Lin Black, signing singly, the undersigned

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% stockholder of Xcyte Therapies, Inc. (the
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, 3, 4 or rt, and timely file such form or report with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
 - (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in th

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, nece poses as the undersigned might or could do if personally present, with full power of substitution of revocation, hereby ratifying and confirming all that such attorn

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersiq &nb
IN WITNESS HEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of March, 2004.

/s/ ROBERT L KIRKMAN

Signature

Robert L Kirkman

Print Name